Coherus Oncology (CHRS) vs Jyong Biotech (MENS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Coherus Oncology (CHRS) has outperformed Jyong Biotech (MENS) over the past year, losing 41.2% versus a loss of 96.1%. Coherus Oncology is the larger company by market cap ($165.3 million vs $159.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CHRS | MENS |
|---|---|---|
| Share price | $1.07 | $2.10 |
| Market cap | $165.32M | $159.66M |
| 1-day change | 0.00% | 0.00% |
| YTD return | -24.65% | -46.84% |
| 1-year return | -41.21% | -96.12% |
| 5-year return | -93.71% | — |
| EPS (TTM) | $-1.27 | $-0.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.62 | $63.00 |
| 52-week low | $0.974 | $1.43 |
| Distance from 52-week high | -59.10% | -96.67% |
| Analyst consensus | none | — |
| Avg. price target upside | +624.30% | — |
| Average volume | 1.16M | 45.61K |
| Shares outstanding | 154.50M | 74.23M |
| Employees | 144 | 27 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CHRS has outperformed MENS by 54.9 percentage points over the past year.
About Coherus Oncology
CHRS stock →Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 144 employees
About Jyong Biotech
MENS stock →Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
CHRS vs MENS FAQ
Which is bigger, Coherus Oncology or Jyong Biotech?
Coherus Oncology (CHRS) is larger, with a market capitalization of $165.32M compared with $159.66M for Jyong Biotech (MENS).
Which stock has performed better over the past year, CHRS or MENS?
CHRS returned -41.21% over the past 12 months, compared with -96.12% for MENS (price return, excluding dividends). Past performance does not predict future results.
Are Coherus Oncology and Jyong Biotech in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Coherus Oncology and Biotechnology: Pharmaceutical Preparations for Jyong Biotech.